Although moderate PERK activation in oligodendrocytes is generally believed to protect oligodendrocytes (both mature and remyelinating oligodendrocytes) against inflammatory attacks in immune-mediated demyelinating diseases, a recent study has revealed that PERK may exert deleterious effects on the development of MS. This evidence concerns the gene EIF2AK3 and myeloid sarcoma.